Reported about 1 year ago
Cancer often strikes silently, and with patients getting younger, it has become one of the most feared diseases among the Taiwanese. In response to the irreversible impact of cancer and the huge medical expenses involved, Nanogen Quality Biomedical has combined science and medical expertise to develop the innovative 'SAA Protein Test,' realizing preventive medicine for cancer. This groundbreaking biomedical testing platform, utilizing nanoscale mass spectrometry technology fully integrated with the SAA protein test, is the world's first to combine protein variant barcoding and classification models. Initiated by key technician Dr. Chen Yu-ju, the technology emerged from 20 years of research and clinical trials involving research institutions such as Academia Sinica, National Chiao Tung University, Kaohsiung Medical University, and National Yang Ming Chiao Tung University. Dr. Chen Yu-ju, known for her contributions to the field, played a pivotal role in advancing the technology and served as a lead scientist. The company notes that Taiwan, under Dr. Chen's guidance, participated in the Cancer Moonshot initiative led by former U.S. Vice President Joe Biden in 2016, aiming to enhance effective cancer treatments globally. The company's strength lies in its key biomedical technology for cancer detection, with developed nanoscale mass spectrometry and SAA protein test that can detect stomach and colorectal cancers at an over 85% rate before the second stage. The cancer biomarker detection platform's primary innovation lies in its 'fast, early, and accurate' approach, offering non-invasive blood tests with an accuracy rate exceeding 85%, making it a safer and higher-quality method for gastric and colorectal cancer detection, endorsed by multiple hospitals and renowned health screening centers like Kaohsiung Medical University Hospital and Chi Mei Medical Center.
Source: YAHOO